Clinical Trial

A Study to Evaluate the Efficacy and Safety of CREZET Tablet

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-25; most recent amendment 2025-08-22.
Status change: Recruiting → Active, Not Recruiting 2024-07-01
Trial Details
NCT Number NCT05889143
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Dyslipidemias
Enrollment 15,000 participants
Start Date 2023-05-24
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-24